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Abstract
Introduction: Adiponectin is an adipokine that regulates energy metabolism and insulin sensitivity, but recent
studies have pointed also to a role in inflammation and arthritis. The purpose of the present study was to
investigate the association and effects of adiponectin on inflammation and cartilage destruction in osteoarthritis
(OA).
Methods: Cartilage and blood samples were collected from 35 male OA patients undergoing total knee
replacement surgery. Preoperative radiographs were evaluated using Ahlbäck classification criteria for knee OA.
Circulating concentrations of adiponectin and biomarkers of OA, that is, cartilage oligomeric matrix protein (COMP)
and matrix metalloproteinase 3 (MMP-3), were measured. Cartilage samples obtained at the time of surgery were
cultured ex vivo, and the levels of adiponectin, nitric oxide (NO), IL-6, MMP-1 and MMP-3 were determined in the
culture media. In addition, the effects of adiponectin on the production of NO, IL-6, MMP-1 and MMP-3 were
studied in cartilage and in primary chondrocyte cultures.
Results: Plasma adiponectin levels and adiponectin released from OA cartilage were higher in patients with the
radiologically most severe OA (Ahlbäck grades 4 and 5) than in patients with less severe disease (Ahlbäck grades 1
to 3). Plasma adiponectin concentrations correlated positively with biomarkers of OA, that is, COMP (r = 0.55, P =
0.001) and MMP-3 (r = 0.34, P = 0.046). Adiponectin was released by OA cartilage ex vivo, and it correlated
positively with production of NO (r = 0.43, P = 0.012), IL-6 (r = 0.42, P = 0.018) and MMP-3 (r = 0.34, P = 0.051).
Furthermore, adiponectin enhanced production of NO, IL-6, MMP-1 and MMP-3 in OA cartilage and in primary
chondrocytes in vitro in a mitogen-activated protein kinase (MAPK)-dependent manner.
Conclusions: The findings of this study show that adiponectin is associated with, and possibly mediates, cartilage
destruction in OA.
Introduction
Adiponectin belongs to the adipokine hormones, which
were initially found to be synthesized by white adipose
tissue and to control appetite and metabolism. Adipo-
nectin was discovered in 1995 by Scherer et al.[ 1 ] ,a n d
it was first named Acrp30 (adipocyte complement-
related protein of 30 kDa). Adiponectin has been found
to improve insulin sensitivity [2,3] and to have antiar-
throgenic properties [4]. Interestingly, adiponectin has
also been identified as a regulatory factor in inflamma-
tion and arthritis [5-8].
Adiponectin can be found in synovial fluid from
osteoarthritis (OA) patients [9,10]. Tissues in the joint,
including synovium, meniscus, osteophytes, cartilage,
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tin [10-12]. The biological effects of adiponectin are
mediated through two adiponectin receptor subtypes,
adiponectin receptor type 1 (AdipoR1) and adiponectin
receptor type 2 (AdipoR2), which have been shown to
be expressed in articular cartilage, bone and synovial tis-
sue [13,14].
In arthritis models and in joint tissues, adiponectin
has been postulated to have both pro- and anti-inflam-
matory effects. Adiponectin has been reported to
increase the production of cartilage-degrading matrix
metalloproteinase (MMP) enzymes, cytokines and pros-
taglandin E2 in chondrocytes and in synovial fibroblasts
[11,14-19]. By contrast, intraarticularly injected adipo-
nectin has been reported to mitigate the severity of col-
lagen-induced arthritis in the mouse and to decrease
immunohistochemically detected expression of TNF, IL-
1 and MMP-3 [20]. Recently, high circulating adiponec-
tin was found to correlate with cartilage degradation in
patients with rheumatoid arthritis (RA) [21-23],
although partly contradictory results have also been
published [24,25].
Adiponectin has emerged as a regulator of immune
responses and inflammatory arthritis [5-7], but its role
in OA and cartilage degradation is controversial and, in
many aspects, poorly known. The purpose of the present
study was to investigate whether adiponectin is asso-
ciated with radiographic severity or biomarkers of OA
or with inflammatory and/or destructive factors released
by cartilage samples obtained from OA patients. Since
mitogen-activated protein kinase (MAPK) pathways
have been proposed as therapeutic targets in OA
[26,27], we decided also to study the possible involve-
ment of these pathways in adiponectin-induced
responses in OA cartilage.
Materials and methods
Patients and clinical studies
The patients in this study fulfilled the American College
of Rheumatology classification criteria for OA [28]. Pre-
operative radiographs, blood samples and cartilage tissue
were collected from 35 male patients with OA (means ±
SEM: age = 69.5 ± 1.6 years, body mass index (BMI) =
29.3 ± 0.8 kg/m
2) undergoing total knee replacement
surgery at Coxa Hospital for Joint Replacement, Tam-
pere, Finland. Radiographs were evaluated according to
the Ahlbäck criteria, grades I to V, with grade V repre-
senting the most severe findings [29]. Plasma and serum
samples were stored at -80°C until analyzed for cartilage
oligomeric matrix protein (COMP), MMP-3 and adipo-
nectin. Cartilage samples were processed as described
below, and the amounts of adiponectin, NO, IL-6,
MMP-1 and MMP-3 released by the cartilage ex vivo
during a 42-hour incubation were measured as
described below. The study was approved by the Ethics
Committee of Tampere University Hospital and carried
out in accordance with the Declaration of Helsinki.
Written informed consent was obtained from the
patients.
Cartilage cultures
Leftover pieces of OA cartilage from knee joint replace-
ment surgery were used. Full-thickness pieces of articu-
lar cartilage from femoral condyles, tibial plateaus and
patellar surfaces showing macroscopic features of early
OA were removed aseptically from subchondral bone
with a scalpel, cut into small pieces and cultured in
DMEM with GIBCO GlutaMAX-I supplemented with
penicillin (100 U/ml), streptomycin (100 μg/ml) and
amphotericin B (250 ng/ml) (all from Invitrogen/Life
Technologies, Carlsbad, CA, USA) at 37°C in a humidi-
fied 5% carbon dioxide atmosphere.
Cartilage samples were incubated for 42 hours with
or without adiponectin (recombinant human adiponec-
tin produced in HEK cells; BioVendor Research and
Diagnostic Products, Modřice, Czech Republic) and the
MAPK inhibitors PD98059 (Erk1/2 inhibitor, 10 μM;
Promega, Madison, WI, USA), SB220025 (p38 inhibi-
tor, 0.5 μM; Calbiochem/Merck KGaA, Darmstadt,
Germany) and SP600125 (JNK inhibitor, 10 μM; Cal-
biochem/Merck KGaA). The concentrations of adipo-
nectin and MAPK inhibitors used in the experiments
were based on preliminary experiments and studies
previously carried out in our laboratory [30-32]. After
the experiments, the cartilage explants were weighed
and the results were expressed per milligram of carti-
lage. The culture media were kept at -20°C until
analyzed.
Primary chondrocyte experiments
The leftover pieces of OA cartilage were processed the
same way as cartilage for cartilage cultures (see above).
Cartilage pieces were washed with PBS, and chondro-
cytes were isolated by enzymatic digestion for 16 hours
at 37°C in a shaker by using a collagenase enzyme blend
(1 mg/ml Liberase TM Research Grade medium; Roche,
Mannheim, Germany). Isolated chondrocytes were
washed and plated on 24-well plates (1.5 × 10
5 cells/ml)
in culture medium (DMEM with supplements; see
above) containing 10% fetal bovine serum. Cells were
treated with increasing concentrations of adiponectin
(0.1 to 3 μg/ml) for 24 hours. The culture media were
kept at -20°C until analyzed. Concentrations of NO, IL-
6, MMP-1 and MMP-3 were determined in culture
media as described below. To investigate MAPK activa-
tion (phosphorylation), cells were treated with adiponec-
tin for 30 or 60 minutes and processed for Western blot
analysis.
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Concentrations of nitrite, a stable metabolite of NO in
aqueous solutions, were measured by Griess reaction
[33].
Measurement of adiponectin, COMP, MMP-1, MMP-3 and
IL-6
Concentrations of adiponectin, COMP, MMP-1, MMP-3
a n dI L - 6i np l a s m a ,s e r u ma n d / o rm e d i u ms a m p l e s
were determined by performing ELISA with commercial
reagents (adiponectin, MMP-1 and MMP-3: R&D Sys-
tems Europe Ltd, Abindgon, UK; COMP: BioVendor;
IL-6: Sanquin, Amsterdam, The Netherlands).
Western blot analysis
Western blot analysis was performed as previously
described [34] using the following antibodies: rabbit
anti-human pAb inducible nitric oxide synthase
(iNOS), actin and c-Jun N-terminal kinase (JNK) anti-
bodies, and horseradish-conjugated goat anti-rabbit
immunoglobulin G antibody from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA) and rabbit anti-human
pAb p38, phospho-p38, phospho-JNK, extracellular sig-
nal-regulated kinase 1/2 (Erk1/2) and phospho-Erk1/2
antibodies from Cell Signaling Technology, Inc (Bev-
erly, MA, USA).
Statistical analysis
Data were analyzed using SPSS version 17.0 for Win-
dows software (SPSS Inc, Chicago, IL, USA) and Graph-
Pad InStat version 3.00 software (GraphPad Software,
San Diego, CA, USA). The results are presented as
means ± SEM unless otherwise indicated. Pearson’sc o r -
relation analysis was carried out, and r values over +0.3
and under -0.3 were considered to indicate a correlation.
Differences between groups were tested by one-way ana-
lysis of variance (ANOVA) or repeated-measures
ANOVA, followed by Fisher’s least significant difference
test or the Bonferroni correction for multiple compari-
sons when appropriate. P-values less than 0.05 were
considered significant. Standard multiple regression ana-
lysis was used to predict circulating biomarker levels
(COMP and MMP-3) when adiponectin, age and BMI
were set as independent variables. Nonstandardized
regression coefficients (b) and coefficients of determina-
tion squared (R
2) with the related P-values were calcu-
lated. Binary logistic regression was used to compute
(BMI or age-adjusted) ORs for plasma adiponectin and
adiponectin released by cartilage to predict the most
severe radiographic findings (Ahlbäck grade 4 or 5 vs
grades 1 to 3). A statistician was consulted regarding
the statistical analysis.
Results
Correlation between plasma adiponectin and biomarkers
of osteoarthritis
Thirty-five male OA patients were included in the study.
Mean adiponectin concentration in plasma was 2.5 ± 0.2
μg/ml, and no correlation between plasma adiponectin
and BMI was found (r = -0.15, P = 0.379). Interestingly,
adiponectin correlated positively with the biomarkers of
OA, that is, COMP (r = 0.55, P = 0.001) (Figure 1A)
and MMP-3 (r = 0.34, P = 0.046) (Figure 1B), pointing
to a possible connection between adiponectin and carti-
lage matrix degradation.
In multiple regression analysis, where serum COMP
was set as a dependent variable and plasma adiponectin,
age and BMI were set as predictive variables,
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Figure 1 Adiponectin correlates with biomarkers of OA.
Scatterplot showing positive correlations between plasma
adiponectin and biomarkers of osteoarthritis (OA), serum cartilage
oligomeric matrix protein (COMP) (A) and plasma matrix
metalloproteinase 3 (MMP-3) (B). N = 35 OA patients.
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1-U change in adiponectin) = 1.7; P = 0.010), but not
BMI (b = -0.10, P = 0.566) or age (b = 0.14, P = 0.160),
was a significant determinant of COMP (R
2 =0 . 3 9a n d
P = 0.001 for model). Also, adiponectin was a significant
determinant of MMP-3 when it was set alone as an
independent variable (b = 0.85, P = 0.046; R
2 = 0.12 and
P = 0.046 for model). Addition of BMI or age as inde-
pendent variables did not improve the model (R
2 = 0.15,
P = 0.070 or R
2 = 0.14, P = 0.089, respectively).
Plasma adiponectin levels and radiographic severity of
osteoarthritis
Preoperative radiographs of the knees were evaluated by
Ahlbäck classification from grades 1 to 5, with grade 5
representing the most severe findings [29]. Grades 1 and
2, and 4 and 5 were combined to create more equally dis-
tributed subgroups. Mean plasma adiponectin concentra-
tions were higher in the grades 4 and 5 group than in the
grade 3 and grades 1 and 2 groups (Figure 2A), but there
was no difference between the grades 1 and 2 group and
the grade 3 group. There were no significant differences
in age or BMI between the radiographic subgroups, but
serum COMP was higher in the grades 4 and 5 group
than in the grade 3 group and the grades 1 and 2 group
(P =0 . 0 1 2a n dP = 0.006, respectively) (Table 1). Binary
logistic regression analysis was used to further evaluate
whether adiponectin is associated with the radiographic
severity of OA (Ahlbäck grades 4 and 5 group vs Ahlbäck
grades 1 to 3 group). When set alone in the model,
plasma adiponectin and cartilage culture medium adipo-
nectin, but not BMI or age, were significant explanatory
factors of radiographic severity (Table 2). After adjusting
for BMI, plasma adiponectin was a significant predictor
of disease severity and almost statistically significant after
adjusting for age (Table 2). Adiponectin measured in the
cartilage culture media was a significant predictor of OA
severity after controlling for age and BMI (Table 2).
Production of adiponectin and inflammatory and/or
degrading factors by osteoarthritis cartilage ex vivo
Cartilage samples were obtained during joint replacement
surgery from the same patients from whom the preopera-
tive radiographs and the blood samples had been collected
(see above), and tissue culture experiments were carried
out. The amounts of adiponectin, NO, IL-6, MMP-1 and
MMP-3 released from the cartilage into the culture med-
ium during 42-hour incubation were measured. Adiponec-
tin release was increased in patients with the
radiographically most severe OA (Ahlbäck grades 4 and 5)
as compared to patients in grades 1 and 2 and those in
grade 3 (P = 0.004 and P < 0.001, respectively) (Figure 2B).
Interestingly, adiponectin levels in the cartilage culture
media correlated positively with those of NO (r =0 . 4 3 ,P
= 0.012) (Figure 3A), IL-6 (r = 0.42, P = 0.018) (Figure 3B)
and MMP-3 (r = 0.34, P = 0.051) (Figure 3C), whereas no
correlation between adiponectin and MMP-1 production
was found (r =0 . 1 7 ,P = 0.31).
Effect of adiponectin on osteoarthritis cartilage and
primary chondrocytes in vitro
To further evaluate the role of adiponectin in OA, we
studied the effect of this adipokine on MAPK
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Figure 2 Adiponectin levels in plasma and those released by
cultured cartilage were higher in patients with radiologically
more severe osteoarthritis. Adiponectin levels in plasma (A) and
the amount of adiponectin released by osteoarthritis (OA) cartilage
samples into culture media (B) in OA patients classified according
to the severity of knee OA evaluated using the Ahlbäck grading
scale. Horizontal solid and dashed bars within the boxes represent
the median and mean, respectively. Boxes represent the
interquartile range. Lines outside boxes represent minimums and
maximums. Outliers are indicated.
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Page 4 of 11phosphorylation (that is, activation) and on NO, IL-6,
MMP-1 and MMP-3 production in primary chondro-
cytes from OA patients. Adiponectin treatment resulted
in time-dependent phosphorylation of p38, Erk1/2 and
JNK in primary OA chondrocytes that was obvious
within 30 minutes and decreased toward baseline by 60
minutes (Figure 4). Adiponectin also enhanced NO, IL-
6, MMP-1 and MMP-3 production in primary OA
chondrocytes in a dose-dependent manner (Figure 5).
Because cartilage matrix is an important regulator of
chondrocyte metabolism, we wanted to investigate the
effects of adiponectin on OA cartilage in tissue culture.
Owing to the limited amount of tissue available for the
experiments, one concentration of adiponectin (1 μg/ml)
was selected based on the cell culture studies (Figure 5)
and previously published data on adiponectin levels in
OA synovial fluid [9,10,12,35]. Adiponectin enhanced
NO, IL-6, MMP-1 and MMP-3 production and iNOS
expression in OA cartilage culture, and their production
was suppressed by the p38 MAPK inhibitor SB220025
(0.5 μM) (Figure 6). In addition, the Erk1/2 inhibitor
PD98059 (10 μM) and the JNK inhibitor SP600125 (10
μM) inhibited adiponectin-induced production of IL-6
and NO, as well as expression of iNOS, in a statistically
significant manner, whereas their effect on MMP-1 and
MMP-3 was smaller and did not reach statistical signifi-
cance (Figure 6).
Discussion
Adiponectin is found in OA joints, and proinflammatory
and catabolic effects have been reported [9,10,13-19].
On the basis of our findings of the present study, we
show for the first time that the circulating adiponectin
concentrations correlate positively with the levels of the
widely used biomarkers of OA, that is, COMP and
MMP-3, and that plasma adiponectin levels, as well as
adiponectin levels released by cultured cartilage, are
associated with the radiographic severity of OA. Inter-
estingly, the amount of adiponectin released by OA car-
tilage ex vivo also correlated positively with the
production of inflammatory mediators NO and IL-6 and
with the matrix-degrading enzyme MMP-3. Further-
more, adiponectin, when added at physiological concen-
trations to cultures of intact human OA cartilage or
primary OA chondrocytes, enhanced the production of
inflammatory and/or destructive factors NO, IL-6,
MMP-1 and MMP-3. These findings suggest that adipo-
nectin is associated with cartilage matrix degradation
and has a role in the pathogenesis or as a biomarker in
OA.
In the present study, we measured circulating levels of
COMP and MMP-3 to evaluate the degree of ongoing
cartilage destruction in OA [36]. The level of serum
COMP has been shown to correlate with the grade of
OA assessed by the radiological score [37], which we
also observed in this study. Also, the concentrations of
MMP-3 have been reported to associate with joint space
narrowing [38]. The present results demonstrate for the
first time that plasma adiponectin levels correlate with
COMP and MMP-3, suggesting an association between
adiponectin and the degree of ongoing cartilage matrix
degradation.
Table 1 Plasma adiponectin levels and clinical characteristics of patients in radiographic subgroups
Radiographic severity of osteoarthritis by Ahlbäck classification
Patient characteristics Grades 1 and 2
(n = 11)
Grade 3
(n = 16)
Grades 4 and 5
(n =8 )
Total (N = 35) P-values
Adiponectin (μg/ml) 2.4 (0.4) 2.1 (0.2) 3.5 (0.5) 2.5 (0.2) 0.03
Age (years) 68.7 (3.0) 67.3 (2.6) 75.0 (2.0) 69.5 (1.6) 0.17
BMI (kg/m
2) 28.7 (1.1) 29.8 (1.4) 29.0 (1.6) 29.3 (0.8) 0.84
COMP (U/L) 10.6 (1.1) 11.7 (1.0) 17.0 (2.4) 12.6 (0.9) 0.01
MMP-3 (ng/ml) 9.6 (1.1) 9.2 (0.6) 10.9 (1.5) 9.7 (0.6) 0.52
BMI = body mass index; COMP = cartilage oligomeric matrix protein; MMP-3 = matrix metalloproteinase 3. Values are means (SEM). P-values refer to the
significance of the comparison of the three groups calculated by analysis of variance.
Table 2 Association of adiponectin and radiographic severity of osteoarthritis
Ahlbäck grades 4 and 5 Ahlbäck grades 1 to 3
Patient characteristics Crude OR 95% CI P-values Adjusted OR 95% CI P-values
Plasma adiponectin (μg/ml) 2.2 1.1 to 4.3 0.022 2.2
a 1.1 to 4.4 0.022
1.9
b 0.9 to 3.8 0.090
Culture media adiponectin (pg/mg cartilage) 1.1 1.0 to 1.2 0.007 1.1
a 1.0 to 1.2 0.007
1.1
b 1.0 to 1.2 0.016
BMI (kg/m
2) 1.0 0.8 to 1.2 0.852
Age (years) 1.1 1.0 to 1.3 0.078
aAdjusted for BMI.
bAdjusted for age. Odds ratios are given for Ahlbäck grades 4 and 5 group vs grades 1 to 3 group.
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ponectin amounts released by cultured OA cartilage ex
vivo were higher in patients with radiographically
advanced OA (grades 4 and 5 according to the Ahlbäck
classification system) than in patients with less severe
disease (Ahlbäck grades 1 to 3). This suggests that adi-
ponectin is associated with cartilage degradation in
patients with OA. Our results are supported by the
recent studies by Ebina et al.[ 2 1 ] ,G i l e set al.[ 2 2 ]a n d
Klein-Wieringa et al. [23], who showed that circulating
adiponectin correlates with joint erosions in RA
patients. Additional support for our findings is provided
by the study of Laurberg et al. [39], who reported ele-
vated plasma adiponectin concentrations in OA patients
as compared to healthy controls. In our study, adiponec-
tin released by cultured cartilage also correlated posi-
tively with NO, IL-6 and MMP-3 production in the
cartilage.
Two recent studies have reported somewhat different
findings on the association between plasma adiponectin
levels and radiographic findings. In the study by Honsa-
wek et al. [24], adiponectin concentrations in plasma
and synovial fluid were lower in patients with more
severe knee OA measured according to the Kellgren-
Lawrence Grading Scale. After they adjusted for gender,
age and BMI, their plasma findings became nonsignifi-
cant, but the differences between adiponectin levels in
synovial fluid within the radiographic groups remained
significant. Most of their patients were female, which
may at least partly explain the differences between their
results and ours. Also, the two different radiographic
scaling systems emphasize different findings. We chose
to use Ahlbäck grading, since it tends to divide the end-
stage OA patients less roughly than the Kellgren-Lawr-
ence Grading Scale, as reported by, for example, Peters-
son et al. [40]. Accordingly, most (80%) of our patients
were scaled into the most severe Kellgren-Lawrence
grade (grade 4). We included only male patients in the
present study because gender is likely to be a confound-
ing factor.
A study by Yusuf et al. [25] revealed that higher levels
of plasma adiponectin decreased the risk for hand OA
progression during a 6-year follow-up period as mea-
sured by radiographic changes. The findings of that
study appear to be somewhat contradictory to our
results and to those reported by the other research
groups mentioned above. The differences may be
explained by many factors, including different methodol-
ogies used to measure adiponectin, differences in patient
characteristics and study protocols, gender differences
(most of the patients in the study by Yusuf et al.w e r e
women) and possibly even by differences in the patho-
physiologies of hand and knee OA. It is also possible
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Figure 3 Ex vivo cartilage releases adiponectin and its
concentration correlates with NO, IL-6 and MMP-3 production.
Scatterplots show positive correlations between adiponectin and
NO (A), IL-6 (B) and matrix metalloproteinase 3 (MMP-3) (C)
released by osteoarthritis (OA) cartilage into the culture medium.
Cartilage samples were collected from 35 OA patients undergoing
knee replacement surgery.
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Page 6 of 11that the significance of adiponectin varies according to
the phase and severity of the OA process. It is note-
worthy that all our patients had advanced OA and were
undergoing joint replacement surgery. This made it pos-
sible to obtain simultaneous cartilage and blood sam-
ples. Lack of patients with less severe OA, however,
limits our ability to generalize the results to milder
cases.
An inverse relationship between adiponectin levels and
BMI, especially visceral fat, has been reported in studies
in which an endocrinological approach was used [41].
However, no correlation between adiponectin and BMI
was found in several recent clinical studies in which
patients with OA or RA were investigated [35,39,42].
This was also the case within our group of OA patients.
This may be explained by the fact that circulating con-
centrations of adiponectin can be regulated by various
hormonal, nutritional or pharmacological factors and
that adiponectin is produced not only by white adipose
tissue but by other tissues as well [41]. The question
remains open whether there is such a systemic factor
that affects the adiponectin levels in patients with
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Figure 4 Adiponectin induces activation of mitogen-activated protein kinases in human primary chondrocytes. The effect of adiponectin
(3 μg/ml) on mitogen-activated protein kinase (MAPK) phosphorylation in human primary chondrocytes obtained from patients with OA. The
figure shows the results of a representative experiment which was repeated three times (that is, with cells from three donors) with similar
results. MAPKs were determined by Western blot analysis at baseline and at 30 and 60 minutes after addition of adiponectin. Erk1/2 =
extracellular signal-regulated kinase 1/2; JNK: c-Jun N-terminal kinase.
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Figure 5 Adiponectin enhances NO, IL-6, MMP-1 and MMP-3 production in human primary chondrocytes in a dose-dependent
manner. Chondrocytes obtained from patients with osteoarthritis (OA) were treated with increasing concentrations of adiponectin (0.1 to 3 μg/
ml). Concentrations of NO (A), IL-6 (B), matrix metalloproteinase 1 (MMP-1) (C) and MMP-3 (D) were measured by the Griess reaction and ELISA
in the culture medium after 24-hour incubation. The figure shows the results of a representative experiment which was repeated three times
(that is, with cells from three donors) with similar results. Results are expressed as means ± SEM (n = 4). *P < 0.05 and ***P < 0.001 compared to
the control sample.
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Page 7 of 11arthritis or whether the joint disease itself rather than
BMI might be a greater explanatory factor in defining
the adiponectin levels in these patients.
As the clinical data suggest that the amount of adipo-
nectin released by cartilage is related to the severity of
cartilage degradation, we decided to study its possible
mechanisms in OA cartilage. In agreement with recent
findings [11,14-16,18], we found that adiponectin stimu-
lated human OA cartilage and primary OA chondro-
cytes to produce NO, IL-6, MMP-1 and MMP-3, which
are proinflammatory and catabolic mediators in OA
[43-50]. In agreement with these findings, adiponectin
was very recently reported to increase the production of
chemokine IL-8 in human chondrocytes [19]. MAPK
inhibitors are under development for treatment of OA
[26,27], and MAPK pathways have been reported to be
activated by adiponectin [51,52]. Therefore, we studied
whether MAPK signaling pathways are also activated by
adiponectin in articular chondrocytes and whether they
might mediate adiponectin’s effects on NO, IL-6, MMP-
1 and MMP-3 production. Adiponectin was found to
activate the kinases p38, JNK and Erk1/2 at physiologi-
cally relevant concentrations. The p38 inhibitor
decreased the production of all factors studied in a
statistically significant manner, whereas Erk1/2 was
involved in adiponectin-induced iNOS expression and
NO production and JNK was involved in NO, iNOS and
IL-6 production. These results, together with recently
published findings [14,18], show that MAPKs, especially
p38, are significant pathways in adiponectin signaling in
chondrocytes. Also, MAPK inhibitors are likely to
attenuate adiponectin-induced gene expression in OA
cartilage.
Adipokines, that is, hormones secreted by adipose tis-
sue, have emerged as important modulating agents, not
only in energy metabolism and appetite but also in the
immune system and inflammation [53], and they are
l i k e l yt oh a v ear o l ei nm e d i a t i n gt h ec o n n e c t i o n
between obesity and chronic inflammatory diseases. The
actions of adiponectin, leptin, resistin and other, less
studied adipokines in OA and other rheumatic diseases
have recently been reviewed by Gómez et al. [7] and by
Neumann et al. [8]. The most studied adipokine in the
pathophysiology of arthritis is leptin, which has been
proven to have proinflammatory and catabolic roles in
OA [8,19,54-58]. Knowledge about adiponectin in joint
diseases has accumulated only lately. The present
results, together with those described in the other recent
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Figure 6 Mitogen-activated protein kinase pathways are involved in adiponectin induced NO, IL-6, MMP-1 and MMP-3 production in
osteoarthritis cartilage. The effects of mitogen-activated protein kinase inhibitors on adiponectin-induced NO production (A), inducible nitric
oxide synthase (iNOS) expression (B), IL-6 production (C), matrix metalloproteinase 1 (MMP-1) production (D) and MMP-3 production (E) in
human osteoarthritis cartilage. Cartilage explants were incubated for 42 hours with adiponectin (1 μg/ml) and the inhibitor indicated. Samples
were collected from six patients in (A) and (B) and from five patients in (C) through (E). Results are expressed as means ± SEM.
#P < 0.1, *P <
0.05, **P < 0.01 and ***P < 0.001 compared to explants treated with adiponectin alone. PD98059 = extracellular signal-regulated kinase 1/2
(Erk1/2) inhibitor; SB220025 = p38 inhibitor; SP600125 = c-Jun N-terminal kinase (JNK) inhibitor. The inhibitor concentrations used were based on
previous studies in our laboratory [30-32].
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Page 8 of 11reports, strongly suggest a proinflammatory and cata-
bolic role for adiponectin in OA and RA cartilage.
Conclusions
We found that adiponectin was associated with markers
and signs of cartilage degradation, that is, with circulat-
ing concentrations of COMP and MMP-3 and with
radiographic severity of OA. Adiponectin was released
by OA cartilage ex vivo, and it correlated with produc-
tion of NO, IL-6 and MMP-3, which are important
mediators in the pathogenesis of OA. Subsequent in
vitro studies demonstrated that adiponectin, when added
to the culture media, enhanced the production of NO,
IL-6, MMP-1 and MMP-3 in OA cartilage and primary
OA chondrocytes. Adiponectin also activated p38, Erk1/
2 and JNK in chondrocytes, and the adiponectin-
induced production of NO, IL-6, MMP-1 and MMP-3
were mediated by MAPKs, especially by p38. These
findings strongly suggest that adiponectin is involved in
the pathogenesis of joint inflammation and cartilage
destruction in OA and may be a target for disease-mod-
ifying drug development.
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